Conyers advises Hony Capital Fund V and New Good Management on privatisation of Simcere
Conyers Dill & Pearman has advised Hony Capital Fund V and New Good Management on the $495m (£300m) privatisation of Simcere Pharmaceutical Group from the New York Stock Exchange (NYSE) by way of merger.
Simcere is a pharmaceutical company specialising in the development, manufacture and marketing of branded and proprietary pharmaceuticals in China.
Conyers co-chair David Lamb and associate Angie Chu, both based in Conyers’ Hong Kong office, acted in this matter. They worked alongside Cleary Gottlieb Steen & Hamilton and Shearman & Sterling.
News from Conyers Dill & Pearman
Briefings from Conyers Dill & Pearman
The offshore world has seen an increase in insolvency matters raising cross-border issues together with a clear trend of judicial inventiveness.
The Cayman government has published the Directors Registration and Licensing Bill 2014, which seeks to regulate directors of certain entities established in the Cayman Islands.